AB Science Identifies Biomarker to Assess Masitinib
AB Science announces the identification of a plasma biomarker capable of assessing the activity of masitinib in the treatment of amyotrophic lateral sclerosis and identifying patients with pro-inflammatory microglia. This biomarker will be integrated into the phase 3 programs of masitinib.
Broad Applications of the Identified Biomarker
The identified biomarker will be used to assess the activity of masitinib in amyotrophic lateral sclerosis (ALS), as well as in progressive forms of multiple sclerosis and Alzheimer's disease. According to Professor Olivier Hermine, president of the scientific committee of AB Science, this biomarker presents normal plasma levels in clinically isolated syndrome, is elevated in relapsing-remitting forms of multiple sclerosis during flare-ups, and in progressive forms, which corresponds to the involvement of microglia in these pathologies.
Integration into Phase 3 Masitinib Program
The biomarker will be integrated into the phase 3 program of masitinib in ALS, as well as trials in progressive multiple sclerosis and Alzheimer's disease, in order to validate the mechanism of action of masitinib in humans and its clinical relevance. Once validated, it could facilitate registration by determining which patients respond best to the treatment. The biomarker remains confidential for patent protection reasons.
